A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222

In the era of globally predominant omicron strains, a COVID-19 booster vaccine is needed. Our study aimed to evaluate the immunogenicity of a half-dose BNT162b2 booster after AZD1222 in healthy adults. A randomized trial of volunteers aged 18–69 years who received two-dose AZD1222 was conducted. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Nantanee, Rapisa, Jantarabenjakul, Watsamon, Jaru-Ampornpan, Peera, Sodsai, Pimpayao, Himananto, Orawan, Athipunjapong, Jitthiwa, Sophonphan, Jiratchaya, Nanthapisal, Sira, Hirankarn, Nattiya, Puthanakit, Thanyawee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230769/
https://www.ncbi.nlm.nih.gov/pubmed/35746522
http://dx.doi.org/10.3390/vaccines10060914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230769/
https://www.ncbi.nlm.nih.gov/pubmed/35746522
http://dx.doi.org/10.3390/vaccines10060914

Ejemplares similares